Sri Lanka 2026 Regulatory Update: GL-037 Low-Risk Pathway

1. Key takeaways

The main line of Sri Lankan device regulation in 2025 and 2026 is procedural consolidation plus low-risk stratification. Three verifiable institutional milestones define it: (1) guideline GL-034 took effect on 2025-07-23, establishing the consolidated dossier structure; (2) the reliance pathway took effect in October 2025, aimed at products already approved in reference countries; and (3) the low-risk guideline GL-037 took effect on 2026-05-13, setting out the Annex 1 listing. Read together, the three milestones show a regulator moving in one direction across two years: gathering what had been scattered processes into single structures, and carving out a faster lane for products that demonstrably carry lower risk.

For companies holding or preparing Sri Lankan submissions across this window, the milestones are not background reading: each one changes what a dossier must contain or which pathway a product may use. An application drafted in mid-2025 under pre-GL-034 assumptions, or a pathway selected before GL-037 was checked against the current Annex 1, will misfire. The timeline in section two therefore functions as a diagnostic instrument — date your project against it before choosing anything else.

2. Legal basis

The timeline below assembles the governing instruments and announcements, each with its date and published source. It is the reference frame against which every Sri Lankan submission prepared in this period should be checked, from the founding Act through to the most recent low-risk guideline.

3. Expert insights

Insight one: the numbering system of the three documents deserves to be memorised on its own. GL-034 (guideline on dossier structure), GL-037 (the low-risk list), F-MDR-042 / 043 / 044 (classification letter acknowledgement / list / application form) and F-MDR-046 (the low-risk submission checklist). In citations, a number is more reliable than a description. Descriptions drift — two correspondents can describe the same guideline differently, and a translated description can wander further still — whereas an identifier pins the reference to the exact instrument the regulator published. Internal correspondence, submission letters and deficiency responses should therefore cite the code first and the descriptive title second, never the description alone.

Insight two: the three exclusion conditions of the low-risk pathway are joined by AND. Products must simultaneously be non-sterile, non-active and without a measuring function. Failing any single condition removes the product from the pathway — which is particularly critical for testing-type devices. Many in vitro diagnostics carry measuring functions by design, and any device presented as sterile, however routine that claim seems, drops out immediately. The check must therefore be run feature by feature against the product’s actual specification, not against its marketing description, and the answer for each condition should be recorded in the project file before the pathway is chosen.

Insight three: 2027-05-09 is a date that belongs in the calendar. After that date, local listed and Class 1 manufacturing sites can rely only on ISO 9001 as the alternative to GMP verification (see article 17 for detail). The significance is planning rather than dramatic change: sites that structured their quality arrangements around the blanket approval window should treat the date as the moment their basis of compliance changes, and any site-level decisions — certification schedules, audits, renovations — should be timed against it rather than discovered when an application is rejected for citing an expired basis.

4. Practical recommendations

The deliverable package GRZAN prepares for clients on Sri Lankan projects always includes a rule-version comparison table — listing, for each basis relied upon, the full title of the document, its number, its effective date and the date it was verified. A quarterly review mechanism is also established: once every quarter, the NMRA website is checked for updates to the GL-037 Annex 1 list, the monthly fee schedule and procedural notices. Frequent rule updates are the number-one risk of this market (see section 9 of the planning document). The comparison table and the quarterly review work as a pair: the table freezes what was true when the submission was prepared, and the review detects when the truth has moved, so that the next submission — or a response to a deficiency letter — is built on the current rule set rather than the remembered one. In a market where guidelines can take effect between one quarter and the next, that pairing is not overhead; it is the mechanism that keeps every downstream document defensible.

5. Verification checklist

• □ The versions of GL-034 (effective 2025-07-23) and GL-037 (effective 2026-05-13) have been recorded
• □ The current GL-037 Annex 1 list has been checked
• □ The monthly fee schedule for the month of submission has been downloaded
• □ A quarterly rule-review mechanism has been established
• □ The current applicability of the reliance pathway (including the Class III exclusion) has been checked

Regulatory information verified as of 28 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across South Asia, including Sri Lanka. Our team prepares dossiers to NMRA expectations, manages submissions and deficiency responses, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com